The regulatory demands of advanced therapeutics manufacturing differ significantly from conventional pharmaceutical manufacturing. With the ever-increasing focus on patient safety and product quality by the FDA and EMA, it is imperative that biomanufacturers in the USA and EU embrace digital solutions to comply with regulations and avoid non-compliance letters.

Join Honeywell to learn more from Dr. Arshad Azwad on how biomanufacturing companies are leveraging digital systems to navigate these challenges.

• Common regulatory pitfalls at biomanufacturing sites identified by the FDA and EMA
• Digital solutions including EBR, MES, QMS, ERP, and LIMS to address regulatory pressure
• Holistic approach to biomanufacturing digital strategy